Olenasufligene relduparvovec
- Generic Name
- Olenasufligene relduparvovec
- Drug Type
- Biotech
- CAS Number
- 2096510-84-6
- Unique Ingredient Identifier
- 7DU50HR4GB
- Background
Olenasufligene relduparvovec is under investigation in clinical trial NCT03612869 (Study of aavrh10-h.sgsh Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)). It is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.
Study of AAVrh10-h.SGSH Gene Therapy in Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- LYSOGENE
- Target Recruit Count
- 20
- Registration Number
- NCT03612869
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath